Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity

References

• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018 May;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 Sep;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016;130:279–294.
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016 Jun;13(6):370–383.
   PubMed Web of Science ®Google Scholar
• Crupi MJF, Bell JC, Singaravelu R. Concise Review: targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells. 2019 Jun;37(6):716–723.
   PubMed Web of Science ®Google Scholar
• Martin NT, Bell JC. Oncolytic Virus Combination Therapy: killing One Bird with Two Stones. Mol Ther. 2018 Jun;26(6):1414–1422.
   PubMed Web of Science ®Google Scholar
• Twumasi-Boateng K, Pettigrew JL, Kwok YYE, et al. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat Rev Cancer. 2018 Jul;18(7):419–432.
   PubMed Web of Science ®Google Scholar
• Vaha-Koskela M, Hinkkanen A. Tumor Restrictions to Oncolytic Virus. Biomedicines. 2014 Apr 17;2(2):163–194.
   PubMedGoogle Scholar
• Musella M, Manic G, De Maria R, et al. Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications. Oncoimmunology. 2017;6(5):e1314424.
   PubMed Web of Science ®Google Scholar
• Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene. 1983 Nov;25(1):21–28.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003 May;9(5):1837–1849.
   PubMed Web of Science ®Google Scholar
• Tolonen N, Doglio L, Schleich S, et al. Vaccinia virus DNA replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. Mol Biol Cell. 2001 Jul;12(7):2031–2046.
   PubMed Web of Science ®Google Scholar
• Chan WM, McFadden G. Oncolytic Poxviruses. Annu Rev Virol. 2014 Sep 1;1;1(1):119–141.
   PubMed Web of Science ®Google Scholar
• Ricordel M, Foloppe J, Pichon C. et al. Oncolytic properties of non-vaccinia poxviruses. Oncotarget. 2018 Nov 13;9(89):35891–35906.
   PubMedGoogle Scholar
• Vanderplasschen A, Mathew E, Hollinshead M. et al. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7544–7549.
   PubMed Web of Science ®Google Scholar
• Vanderplasschen A, Hollinshead M, Smith GL. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol. 1997 Aug;78(Pt 8):2041–2048.
   PubMedGoogle Scholar
• Smith GL, Murphy BJ, Law M. Vaccinia virus motility. Annu Rev Microbiol. 2003;57(1):323–342.
   PubMedGoogle Scholar
• Breitbach CJ, Burke J, Jonker D. et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011 Aug 31;477(7362):99–102.
   PubMed Web of Science ®Google Scholar
• Smith GL, McFadden G. Smallpox: anything to declare? Nat Rev Immunol. 2002 Jul;2(7):521–527.
   PubMed Web of Science ®Google Scholar
• Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med. 2008 Dec;121(12):1058–1064.
   PubMed Web of Science ®Google Scholar
• Vanderplasschen A, Hollinshead M, Smith GL. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol. 1998 Apr;79(4):877–887.
   PubMedGoogle Scholar
• Benhnia MR, Maybeno M, Blum D, et al. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol. 2013 Feb;87(3):1569–1585.
   PubMed Web of Science ®Google Scholar
• Hill C, Carlisle R. Achieving systemic delivery of oncolytic viruses. Expert Opin Drug Deliv. 2019 Jun;16(6):607–620.
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Wallinga J, Teunis P, et al. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med. 2006 Aug;3(8):e272.
   PubMed Web of Science ®Google Scholar
• Buller RM, Smith GL, Cremer K. et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985 [Oct 31-Nov 6];317(6040):813–815.
   PubMed Web of Science ®Google Scholar
• Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361–370.
   PubMed Web of Science ®Google Scholar
• Topolcan O, Holubec L Jr. The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn. 2008 Feb;2(2):129–141.
   PubMedGoogle Scholar
• Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark Med. 2018 Sep;12(9):1035–1048.
   PubMed Web of Science ®Google Scholar
• Maroun J, Munoz-Alia M, Ammayappan A, et al. Designing and building oncolytic viruses. Future Virol. 2017 Apr;12(4):193–213.
   PubMed Web of Science ®Google Scholar
• Hughes J, Wang P, Alusi G, et al. Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. Gene Ther. 2015 Jun;22(6):476–484.
   PubMed Web of Science ®Google Scholar
• Puhlmann M, Brown CK, Gnant M, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 2000 Jan;7(1):66–73.
   PubMed Web of Science ®Google Scholar
• Deng L, Fan J, Ding Y, et al. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Oncotarget. 2017 Jun 20;8(25): 40533–40543.
   PubMedGoogle Scholar
• Foloppe J, Kempf J, Futin N, et al. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism. Mol Ther Oncolytics. 2019 Sep 27;14:1–14.
   PubMed Web of Science ®Google Scholar
• Chaurasiya S, Chen NG, Lu J. et al. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models. Cancer Gene Ther. 2019 Jun 17;27:125–135.
   PubMed Web of Science ®Google Scholar
• Gammon DB, Gowrishankar B, Duraffour S. et al. Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis. PLoS Pathog. 2010 Jul 8;6(7):e1000984.
   PubMed Web of Science ®Google Scholar
• Potts KG, Irwin CR, Favis NA, et al. Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models. EMBO Mol Med. 2017 May;9(5):638–654.
   PubMed Web of Science ®Google Scholar
• Cripe TP, Ngo MC, Geller JI, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015 Mar;23(3):602–608.
   PubMed Web of Science ®Google Scholar
• Buller RM, Chakrabarti S, Cooper JA, et al. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol. 1988 Mar;62(3):866–874.
   PubMed Web of Science ®Google Scholar
• McCart JA, Ward JM, Lee J. et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001 Dec 15;61(24):8751–8757.
   PubMed Web of Science ®Google Scholar
• Thomson BJ. Viruses and apoptosis. Int J Exp Pathol. 2001 Apr;82(2):65–76.
   PubMed Web of Science ®Google Scholar
• Wasilenko ST, Meyers AF, Vander Helm K, et al. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J Virol. 2001 Dec;75(23):11437–11448.
   PubMed Web of Science ®Google Scholar
• Heinkelein M, Pilz S, Jassoy C. Inhibition of CD95 (Fas/Apo1)-mediated apoptosis by vaccinia virus WR. Clin Exp Immunol. 1996 Jan;103(1):8–14.
   PubMed Web of Science ®Google Scholar
• Pelin A, Foloppe J, Petryk J, et al. Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. Mol Ther Oncolytics. 2019 Sep 27;14:246–252.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Naik A, O’Malley ME. et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res. 2005 Nov 1;65(21):9991–9998.
   PubMed Web of Science ®Google Scholar
• Ali AN, Turner PC, Brooks MA, et al. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology. 1994 Jul;202(1):305–314.
   PubMed Web of Science ®Google Scholar
• Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J Virol. 1996 Sep;70(9):6479–6485.
   PubMed Web of Science ®Google Scholar
• Kettle S, Blake NW, Law KM. et al. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model. Virology. 1995 Jan 10;206(1):136–147.
   PubMed Web of Science ®Google Scholar
• España L, Fernández Y, Rubio N, et al. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res Treat. 2004 Sep;87(1):33–44.
   PubMed Web of Science ®Google Scholar
• Um HD. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: a review focusing on mitochondrial respiration and reactive oxygen species. Oncotarget. 2016 Feb 2;7(5):5193–5203.
   PubMedGoogle Scholar
• Trisciuoglio D, Tupone MG, Desideri M. et al. BCL-XL overexpression promotes tumor progression-associated properties. Cell Death Dis. 2017 Dec 13;8(12):3216.
   PubMedGoogle Scholar
• Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis. 2019 Feb 21;10(3):177.
   PubMedGoogle Scholar
• Kvansakul M, Yang H, Fairlie WD, et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ. 2008 Oct;15(10):1564–1571.
   PubMed Web of Science ®Google Scholar
• Aoyagi M, Zhai D, Jin C, et al. Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci. 2007 Jan;16(1):118–124.
   PubMed Web of Science ®Google Scholar
• Postigo A, Cross JR, Downward J, et al. Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Differ. 2006 Oct;13(10):1651–1662.
   PubMed Web of Science ®Google Scholar
• Maluquer de Motes C, Cooray S, Ren H, et al. Inhibition of apoptosis and NF-kappaB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog. 2011 Dec;7(12):e1002430.
   PubMed Web of Science ®Google Scholar
• Postigo A, Way M. The vaccinia virus-encoded Bcl-2 homologues do not act as direct Bax inhibitors. J Virol. 2012 Jan;86(1):203–213.
   PubMed Web of Science ®Google Scholar
• Eaglesham JB, Pan Y, Kupper TS, et al. Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS-STING signalling. Nature. 2019 Feb;566(7743):259–263.
   PubMed Web of Science ®Google Scholar
• Meng X, Jiang C, Arsenio J, et al. Vaccinia virus K1L and C7L inhibit antiviral activities induced by type I interferons. J Virol. 2009 Oct;83(20):10627–10636.
   PubMed Web of Science ®Google Scholar
• Unterholzner L, Sumner RP, Baran M, et al. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog. 2011 Sep;7(9):e1002247.
   PubMed Web of Science ®Google Scholar
• Ferguson BJ, Benfield CT, Ren H, et al. Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol. 2013 Sep;94(Pt 9):2070–2081.
   PubMedGoogle Scholar
• Mann BA, Huang JH, Li P, et al. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J Interferon Cytokine Res. 2008 Jun;28(6):367–380.
   PubMed Web of Science ®Google Scholar
• Colamonici OR, Domanski P, Sweitzer SM. et al. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem. 1995 Jul 7;270(27):15974–15978.
   PubMed Web of Science ®Google Scholar
• Diamond MS, Kinder M, Matsushita H. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011 Sep 26;208(10):1989–2003.
   PubMed Web of Science ®Google Scholar
• Kirn DH, Wang Y, Le Boeuf F, et al. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 2007 Dec;4(12):e353.
   PubMed Web of Science ®Google Scholar
• Symons JA, Adams E, Tscharke DC, et al. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. J Gen Virol. 2002 Nov;83(Pt 11):2833–2844.
   PubMedGoogle Scholar
• Fahy AS, Clark RH, Glyde EF, et al. Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol. 2008 Oct;89(Pt 10):2377–2387.
   PubMedGoogle Scholar
• Mazzon M, Castro C, Roberts LD, et al. A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism. J Gen Virol. 2015 Feb;96(Pt 2):395–407.
   PubMedGoogle Scholar
• Kluczyk A, Siemion IZ, Szewczuk Z, et al. The immunosuppressive activity of peptide fragments of vaccinia virus C10L protein and a hypothesis on the role of this protein in the viral invasion. Peptides. 2002 May;23(5):823–834.
   PubMed Web of Science ®Google Scholar
• Liu R, Moss B. Vaccinia Virus C9 Ankyrin Repeat/F-Box Protein Is a Newly Identified Antagonist of the Type I Interferon-Induced Antiviral State. J Virol. 2018 May 1;92(9). DOI:10.1128/JVI.00053-18.
   Web of Science ®Google Scholar
• Stuart JH, Sumner RP, Lu Y, et al. Vaccinia Virus Protein C6 Inhibits Type I IFN Signalling in the Nucleus and Binds to the Transactivation Domain of STAT2. PLoS Pathog. 2016 Dec;12(12):e1005955.
   PubMed Web of Science ®Google Scholar
• Scutts SR, Ember SW, Ren H. et al. DNA-PK Is Targeted by Multiple Vaccinia Virus Proteins to Inhibit DNA Sensing. Cell Rep. 2018 Nov 13;25(7):1953–65 e4.
   PubMed Web of Science ®Google Scholar
• Jha P, Kotwal GJ. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J Biosci. 2003 Apr;28(3):265–271.
   PubMed Web of Science ®Google Scholar
• Girgis NM, Dehaven BC, Xiao Y, et al. The Vaccinia virus complement control protein modulates adaptive immune responses during infection. J Virol. 2011 Mar;85(6):2547–2556.
   PubMed Web of Science ®Google Scholar
• DiPerna G, Stack J, Bowie AG. et al. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004 Aug 27;279(35):36570–36578.
   PubMed Web of Science ®Google Scholar
• Ryerson MR, Richards MM, Kvansakul M. et al. Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome. J Virol. 2017 Dec 1;91(23). DOI:10.1128/JVI.01385-17.
   PubMed Web of Science ®Google Scholar
• Kleinpeter P, Remy-Ziller C, Winter E, et al. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1. J Virol. 2019 Jun 1;93(11):11.
   Web of Science ®Google Scholar
• Bravo Cruz AG, Shisler JL. Vaccinia virus K1 ankyrin repeat protein inhibits NF-kappaB activation by preventing RelA acetylation. J Gen Virol. 2016 Oct;97(10):2691–2702.
   PubMedGoogle Scholar
• Willis KL, Patel S, Xiang Y. et al. The effect of the vaccinia K1 protein on the PKR-eIF2alpha pathway in RK13 and HeLa cells. Virology. 2009 Nov 10;394(1):73–81.
   PubMed Web of Science ®Google Scholar
• Shisler JL, Jin XL. The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation. J Virol. 2004 Apr;78(7):3553–3560.
   PubMed Web of Science ®Google Scholar
• Davies MV, Chang HW, Jacobs BL, et al. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol. 1993 Mar;67(3):1688–1692.
   PubMed Web of Science ®Google Scholar
• Carroll K, Elroy-Stein O, Moss B. et al. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-specific protein kinase. J Biol Chem. 1993 Jun 15;268(17):12837–12842.
   PubMed Web of Science ®Google Scholar
• Benfield CT, Ren H, Lucas SJ, et al. Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol. 2013 Jul;94(Pt 7):1647–1657.
   PubMedGoogle Scholar
• Gerlic M, Faustin B, Postigo A. et al. Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7808–7813.
   PubMed Web of Science ®Google Scholar
• Guerra S, Cáceres A, Knobeloch KP, et al. Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog. 2008 Jul 4;4(7):e1000096.
   PubMed Web of Science ®Google Scholar
• Rehm KE, Connor RF, Jones GJ. et al. Vaccinia virus A35R inhibits MHC class II antigen presentation. Virology. 2010 Feb 5;397(1):176–186.
   PubMed Web of Science ®Google Scholar
• Liu H, Juo ZS, Shim AH. et al. Structural basis of semaphorin-plexin recognition and viral mimicry from Sema7A and A39R complexes with PlexinC1. Cell. 2010 Sep 3;142(5):749–761.
   PubMed Web of Science ®Google Scholar
• Czopik AK, Bynoe MS, Palm N, et al. Semaphorin 7A is a negative regulator of T cell responses. Immunity. 2006 May;24(5):591–600.
   PubMed Web of Science ®Google Scholar
• Bahar MW, Kenyon JC, Putz MM, et al. Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog. 2008 Jan;4(1):e5.
   PubMed Web of Science ®Google Scholar
• Clark RH, Kenyon JC, Bartlett NW, et al. Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol. 2006 Jan;87(Pt 1):29–38.
   PubMedGoogle Scholar
• Reading PC, Moore JB, Smith GL. Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med. 2003 May 19;197(10): 1269–1278.
   PubMed Web of Science ®Google Scholar
• Neidel S, Maluquer de Motes C, Mansur DS. et al. Vaccinia virus protein A49 is an unexpected member of the B-cell Lymphoma (Bcl)-2 protein family. J Biol Chem. 2015 Mar 6;290(10):5991–6002.
   PubMed Web of Science ®Google Scholar
• Mansur DS, Maluquer de Motes C, Unterholzner L, et al. Poxvirus targeting of E3 ligase beta-TrCP by molecular mimicry: a mechanism to inhibit NF-kappaB activation and promote immune evasion and virulence. PLoS Pathog. 2013 Feb;9(2):e1003183.
   PubMed Web of Science ®Google Scholar
• Maluquer de Motes C, Smith GL. Vaccinia virus protein A49 activates Wnt signalling by targetting the E3 ligase beta-TrCP. J Gen Virol. 2017 Dec;98(12):3086–3092.
   PubMed Web of Science ®Google Scholar
• Harte MT, Haga IR, Maloney G. et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med. 2003 Feb 3;197(3):343–351.
   PubMed Web of Science ®Google Scholar
• Alcamí A, Khanna A, Paul NL, et al. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J Gen Virol. 1999 Apr;80(Pt 4):949–959.
   PubMedGoogle Scholar
• Dai K, Liu Y, Liu M. et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine. 2008 Sep 15;26(39):5062–5071.
   PubMed Web of Science ®Google Scholar
• Pallett MA, Ren H, Zhang RY. et al. Vaccinia Virus BBK E3 Ligase Adaptor A55 Targets Importin-Dependent NF-kappaB Activation and Inhibits CD8(+) T-Cell Memory. J Virol. 2019 May 15;93(10). DOI:10.1128/JVI.00051-19.
   PubMed Web of Science ®Google Scholar
• Alcamí A, Smith GL. Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol. 1995 Aug;69(8):4633–4639.
   PubMed Web of Science ®Google Scholar
• Kettle S, Alcamí A, Khanna A, et al. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever. J Gen Virol. 1997 Mar;78(Pt 3):677–685.
   PubMedGoogle Scholar
• Di Pilato M, Mejías-Pérez E, Sorzano COS. et al. Distinct Roles of Vaccinia Virus NF-kappaB Inhibitor Proteins A52, B15, and K7 in the Immune Response. J Virol. 2017 Jul 1;91(13). DOI:10.1128/JVI.00575-17.
   PubMed Web of Science ®Google Scholar
• Alcamí A, Smith GL. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 1992 Oct 2;71(1):153–167.
   PubMed Web of Science ®Google Scholar
• Zimmerling S, Waibler Z, Resch T, et al. Interleukin-1beta receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1beta activity produced in various virus-infected antigen-presenting cells. Virol J. 2013 Jan 28;10(1):34.
   PubMedGoogle Scholar
• Zhao J, He S, Minassian A, et al. Recent advances on viral manipulation of NF-kappaB signaling pathway. Curr Opin Virol. 2015 Dec;15:103–111.
   PubMed Web of Science ®Google Scholar
• Lysakova-Devine T, Keogh B, Harrington B. et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010 Oct 1;185(7):4261–4271.
   PubMed Web of Science ®Google Scholar
• Maloney G, Schröder M, Bowie AG. Vaccinia virus protein A52R activates p38 mitogen-activated protein kinase and potentiates lipopolysaccharide-induced interleukin-10. J Biol Chem. 2005 Sep 2;280(35):30838–30844.
   PubMed Web of Science ®Google Scholar
• Tang Q, Chakraborty S, Xu G. Mechanism of vaccinia viral protein B14-mediated inhibition of IkappaB kinase beta activation. J Biol Chem. 2018 Jun 29;293(26):10344–10352.
   PubMed Web of Science ®Google Scholar
• Gedey R, Jin XL, Hinthong O, et al. Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells. J Virol. 2006 Sep;80(17):8676–8685.
   PubMed Web of Science ®Google Scholar
• Sumner RP, Maluquer de Motes C, Veyer DL, et al. Vaccinia virus inhibits NF-kappaB-dependent gene expression downstream of p65 translocation. J Virol. 2014 Mar;88(6):3092–3102.
   PubMed Web of Science ®Google Scholar
• Dobson BM, Tscharke DC. Redundancy complicates the definition of essential genes for vaccinia virus. J Gen Virol. 2015 Nov;96(11):3326–3337.
   PubMedGoogle Scholar
• Carroll MW, Overwijk WW, Chamberlain RS, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 1997 Mar;15(4):387–394.
   PubMed Web of Science ®Google Scholar
• Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccines. 2009 Dec;5(12):867–871.
   PubMed Web of Science ®Google Scholar
• Qin L, Evans DH. Genome scale patterns of recombination between coinfecting vaccinia viruses. J Virol. 2014 May;88(10):5277–5286.
   PubMed Web of Science ®Google Scholar
• Nagata LP, Irwin CR, Hu WG, et al. Vaccinia-based vaccines to biothreat and emerging viruses. Biotechnol Genet Eng Rev. 2018 Apr;34(1):107–121.
   PubMed Web of Science ®Google Scholar
• Paszkowski P, Noyce RS, Evans DH. Live-Cell Imaging of Vaccinia Virus Recombination. PLoS Pathog. 2016 Aug;12(8):e1005824.
   PubMed Web of Science ®Google Scholar
• Ricordel M, Foloppe J, Antoine D. et al. Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency. Cancers (Basel). 2018 Jul 10;10(7):231.
   PubMed Web of Science ®Google Scholar
• Jacobs BL, Langland JO, Kibler KV, et al. Vaccinia virus vaccines: past, present and future. Antiviral Res. 2009 Oct;84(1):1–13.
   PubMed Web of Science ®Google Scholar
• Yang Z, Cao S, Martens CA, et al. Deciphering poxvirus gene expression by RNA sequencing and ribosome profiling. J Virol. 2015 Jul;89(13):6874–6886.
   PubMed Web of Science ®Google Scholar
• Bronte V, Carroll MW, Goletz TJ. et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183–3188.
   PubMed Web of Science ®Google Scholar
• Chen B, Timiryasova TM, Gridley DS. et al. Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy. Cytokine. 2001 Sep 21;15(6):305–314.
   PubMed Web of Science ®Google Scholar
• Wennier ST, Brinkmann K, Steinhäußer C, et al. A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses. PLoS One. 2013;8(8):e73511.
   PubMed Web of Science ®Google Scholar
• Hammond JM, Oke PG, Coupar BE. A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods. 1997 Jun;66(1):135–138.
   PubMed Web of Science ®Google Scholar
• Stritzker J, Huppertz S, Zhang Q, et al. Inducible gene expression in tumors colonized by modified oncolytic vaccinia virus strains. J Virol. 2014 Oct;88(19):11556–11567.
   PubMed Web of Science ®Google Scholar
• Di Pilato M, Mejías-Pérez E, Gómez CE, et al. New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol. 2013 Dec;94(Pt 12):2771–2776.
   PubMedGoogle Scholar
• Di Pilato M, Sánchez-Sampedro L, Mejías-Pérez E, et al. Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression. J Gen Virol. 2015 Aug;96(8):2360–2371.
   PubMedGoogle Scholar
• Sun T, Luo Y, Wang M, et al. Recombinant Oncolytic Vaccinia Viruses Expressing Human beta-Defensin 2 Enhance Anti-tumor Immunity. Mol Ther Oncolytics. 2019 Jun 28;13:49–57.
   PubMed Web of Science ®Google Scholar
• Parviainen S, Ahonen M, Diaconu I, et al. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther. 2014 Feb;21(2):195–204.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim-Schulze S, Kim DW. et al. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 2009 Nov 1;69(21):8516–8525.
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008 Jun;9(6):533–542.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Bell JC, Hwang TH, et al. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594). Oncolytic Virother. 2015;4:25–31.
   PubMed Web of Science ®Google Scholar
• Qin H, Valentino J, Manna S, et al. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther. 2001 Dec;4(6):551–558.
   PubMed Web of Science ®Google Scholar
• Kowalsky SJ, Liu Z, Feist M. et al. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Mol Ther. 2018 Oct 3;26(10):2476–2486.
   PubMed Web of Science ®Google Scholar
• Chen B, Timiryasova TM, Andres ML, et al. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther. 2000 Nov;7(11):1437–1447.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang J, Zhang Y, et al. Vaccinia virus expressing IL-37 promotes antitumor immune responses in hepatocellular carcinoma. Cell Biochem Funct. 2019 Dec;37(8):618–624.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Li J, et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. Oncoimmunology. 2016 Mar;5(3):e1091554.
   PubMed Web of Science ®Google Scholar
• Chard LS, Maniati E, Wang P. et al. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin Cancer Res. 2015 Jan 15;21(2):405–416.
   PubMed Web of Science ®Google Scholar
• Lv C, Su Q, Liang Y. et al. Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem Biophys Res Commun. 2016 Jul 15;476(1):21–28.
   PubMed Web of Science ®Google Scholar
• Gil M, Seshadri M, Komorowski MP. et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1291–300.
   PubMed Web of Science ®Google Scholar
• Komorowski M, Tisonczyk J, Kolakowska A. et al. Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice. Viruses. 2018 Aug 26;10(9):455.
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther. 2011 Apr;19(4):650–657.
   PubMed Web of Science ®Google Scholar
• Li J, O’Malley M, Sampath P, et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia. 2012 Dec;14(12):1115–1121.
   PubMed Web of Science ®Google Scholar
• Sturm JB, Hess M, Weibel S, et al. Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy. J Transl Med. 2012 Jan 11;10(1):9.
   PubMedGoogle Scholar
• Hirvinen M, Capasso C, Guse K, et al. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Mol Ther Oncolytics. 2016 Mar;3:16002.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Bonilla B. et al. Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. Cell Rep. 2016 Apr 12;15(2):264–273.
   PubMed Web of Science ®Google Scholar
• Pan Q, Huang Y, Chen L, et al. SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC. Hum Cell. 2014 Oct;27(4):162–171.
   PubMed Web of Science ®Google Scholar
• Kochneva G, Sivolobova G, Tkacheva A. et al. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016 Nov 8;7(45):74171–74188.
   PubMedGoogle Scholar
• Pearl TM, Markert JM, Cassady KA, et al. Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors. Mol Ther Oncolytics. 2019 Jun;28(13):14–21.
   Google Scholar
• Panelli MC, White R, Foster M. et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med. 2004 Jun 2;2(1):17.
   PubMedGoogle Scholar
• Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications. Principles of administration and management of side effects. In: DeVita VT, Rosenberg SA, Lawrence TS, editors. Biologic Therapy of Cancer, 2nd ed. . Philadelphia: Lippincott Williams & Wilkins; 1995:235–49.
   Google Scholar
• Liu Z, Ge Y, Wang H. et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun. 2018 Nov 8;9(1):4682.
   PubMedGoogle Scholar
• Ziauddin MF, Guo ZS, O’Malley ME, et al. TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther. 2010 Apr;17(4):550–559.
   PubMed Web of Science ®Google Scholar
• Young PA, Morrison SL, Timmerman JM. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol. 2014 Oct;41(5):623–636.
   PubMed Web of Science ®Google Scholar
• Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012 Feb 20;196(4):395–406.
   PubMed Web of Science ®Google Scholar
• Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011 Mar;4(2):165–178.
   PubMed Web of Science ®Google Scholar
• Ishihara J, Ishihara A, Potin L, et al. Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity. Mol Cancer Ther. 2018 Nov;17(11):2399–2411.
   PubMed Web of Science ®Google Scholar
• Ishihara J, Fukunaga K, Ishihara A. et al. Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017 Nov 8;9(415):eaan0401.
   PubMed Web of Science ®Google Scholar
• Chen H, Sampath P, Hou W, et al. Regulating cytokine function enhances safety and activity of genetic cancer therapies. Mol Ther. 2013 Jan;21(1):167–174.
   PubMed Web of Science ®Google Scholar
• Karupiah G, Woodhams CE, Blanden RV. et al. Immunobiology of infection with recombinant vaccinia virus encoding murine IL-2. Mechanisms of rapid viral clearance in immunocompetent mice. J Immunol. 1991 Dec 15;147(12):4327–4332.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Sabzevari H, Yafal AG. et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 1999 Nov 15;59(22):5800–5807.
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Hinterberger M, Testori M. et al. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Nat Commun. 2019 Nov 6;10(1):5041.
   PubMedGoogle Scholar
• Yu F, Wang X, Guo ZS, et al. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther. 2014 Jan;22(1):102–111.
   PubMed Web of Science ®Google Scholar
• Kleinpeter P, Fend L, Thioudellet C, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death −1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5(10):e1220467.
   PubMed Web of Science ®Google Scholar
• Gerriets VA, Danzaki K, Kishton RJ, et al. Leptin directly promotes T-cell glycolytic metabolism to drive effector T-cell differentiation in a mouse model of autoimmunity. Eur J Immunol. 2016 Aug;46(8):1970–1983.
   PubMed Web of Science ®Google Scholar
• Rivadeneira DB, DePeaux K, Wang Y. et al. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity. 2019 Sep 17;51(3):548–60 e4.
   PubMed Web of Science ®Google Scholar
• Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 Aug;18(8):498–513.
   PubMed Web of Science ®Google Scholar
• Fend L, Yamazaki T, Remy C. et al. Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-alpha Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. Cancer Res. 2017 Aug 1;77(15):4146–4157.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Kalinski P, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017 Mar 27;8(1):14754.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Lee WS, Yang H. et al. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Clin Cancer Res. 2019 Mar 1;25(5):1612–1623.
   PubMed Web of Science ®Google Scholar
• Guedan S, Alemany R. CAR-T Cells and Oncolytic Viruses: joining Forces to Overcome the Solid Tumor Challenge. Front Immunol. 2018;9:2460.
   PubMed Web of Science ®Google Scholar
• Park AK, Fong Y, Chen NG, et al. Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors. BioRxiv [Preprint]. 2019 bioRxiv 843052 [posted 2019 Nov 16; cited 2019 Jan 1]: [34 p.]. Available from: https://www.biorxiv.org/content/10.1101/843052v1
   Google Scholar
• Umer BA, Noyce RS, Franczak BC. et al. Deciphering the immunomodulatory capacity of oncolytic vaccinia virus to enhance the immune response to breast cancer. Cancer Immunol Res. 2020; cited 2020 Mar 7.30.10.1158/2326-6066.CIR-19-0703
   Web of Science ®Google Scholar